Reported about 22 hours ago
BioCryst Pharmaceuticals has finalized a deal to sell its European ORLADEYO business to Neopharmed Gentili for up to $264 million, including a $250 million upfront payment. The transaction, expected to close by early October, will help BioCryst eliminate approximately $70 million in future interest costs on its term debt and improve its cash position significantly by the end of 2027. The sale also includes the transfer of BioCryst's European organization, potentially yielding considerable annual operational savings.
Source: YAHOO